Skip to content

US · CADL · BIOTECHNOLOGY

Candel Therapeutics, Inc. (CADL) intrinsic value and stock valuation

$5.04as of 2026-11-21 · Mkt cap 775.93M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Candel Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values CADL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CADL’s statements →

Candel Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Needham, MA 02494 candeltx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-38.18M
20192025
Free cash flow
-$-38.9M
20192025
Total equity
$51.9M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$120K$120K
Operating income-$-48.27M-$-33.37M-$-38.39M-$-34.67M-$-24.65M
Net income-$-38.18M-$-55.18M-$-37.94M-$-18.79M-$-36.12M
EPSd-$-720.92K-$-1.74M-$-1.31M-$-651.98K-$-1.26M
Operating cash flow-$-38.31M-$-27.02M-$-34.24M-$-31.42M-$-22.22M
Capital expenditure-$-590K-$-20K-$-460K-$-1.3M-$-1.83M
Free cash flow-$-38.9M-$-27.04M-$-34.7M-$-32.72M-$-24.05M
Total assets$125.2M$106.9M$41.2M$78.5M$89.2M
Total debt$1.9M$13.5M$22.8M$22.8M$560K
Net debt-$-117.83M-$-89.18M-$-12.65M-$-47.26M-$-82.08M
Total equity$51.9M$66.3M$12.7M$47.7M$64.1M
Cash and short-term investments$119.7M$102.7M$35.4M$70.1M$82.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$120K$120K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$120K$120K
Research and development expenses$30.5M$19.3M$24.5M$20.8M$15.2M
Selling, general and administrative expenses$17.8M$14.1M$13.9M$14.1M$10.7M
Other expenses$0.00$0.00$0.00-$-50K-$-1.08M
Operating expenses$48.3M$33.4M$38.4M$34.8M$24.8M
Cost and expenses$48.3M$33.4M$38.4M$34.8M$24.8M
Interest income$3.92M$1.09M$2.08M$1.22M$0.00
Interest expense$2.12M$2.09M$2.6M$1.71M$50K
Depreciation and amortization$840K$990K$960K$780K$230K
Ebitda-$-35.22M-$-52.1M-$-34.38M-$-16.31M-$-24.42M
Operating income-$-48.27M-$-33.37M-$-38.39M-$-34.67M-$-24.65M
Total other income/expenses, net$10.1M-$-21.81M$450K$15.9M-$-10.4M
Income before tax-$-38.18M-$-55.18M-$-37.94M-$-18.79M-$-36.12M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-38.18M-$-55.18M-$-37.94M-$-18.79M-$-36.12M
Weighted average shares outstanding$53M$31.7M$28.9M$28.8M$28.7M
Weighted average diluted shares outstanding$53M$31.7M$28.9M$28.8M$28.7M
Balance sheet
20252024202320222021
Cash and short-term investments$119.7M$102.7M$35.4M$70.1M$82.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$119.7M$103.8M$36.8M$71.9M$84.9M
Property, plant and equipment, net$0.00$2.73M$4.02M$5.48M$3.84M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$420K$0.00$0.00$270K$420K
Total non-current assets$5.46M$3.06M$4.4M$6.57M$4.26M
Total assets$125.2M$106.9M$41.2M$78.5M$89.2M
Accounts payable$1.13M$240K$420K$380K$1.59M
Short-term debt$450K$10.5M$9.41M$460K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9M$37.5M$14.2M$5.62M$5.36M
Long-term debt$1.46M$3.01M$13.4M$22.3M$560K
Deferred revenue, non-current$0.00$0.00$0.00$140K$0.00
Total non-current liabilities$64.3M$3.01M$14.3M$25.2M$19.7M
Capital lease obligations$0.00$970K$1.49M$1.49M$0.00
Total liabilities$73.3M$40.5M$28.5M$30.8M$25.1M
Common stock$550K$470K$290K$290K$290K
Retained earnings-$-230.39M-$-192.21M-$-137.03M-$-99.09M-$-80.3M
Accumulated other comprehensive income (loss)$0.00-$0.00$0.00$0.00-$-89.2M
Total equity$51.9M$66.3M$12.7M$47.7M$64.1M
Total investments$420K$0.00$0.00$270K$420K
Total debt$1.9M$13.5M$22.8M$22.8M$560K
Net debt-$-117.83M-$-89.18M-$-12.65M-$-47.26M-$-82.08M
Cash flow statement
20252024202320222021
Net income-$-38.18M-$-55.18M-$-37.94M-$-18.79M-$-36.12M
Depreciation and amortization$840K$990K$1.28M$780K$230K
Stock-based compensation$3.82M$5.31M$3.09M$2.31M$2.96M
Change in working capital$2.19M$350K-$-380K$70K-$-880K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$800K-$-180K$40K-$-1.21M$670K
Net cash provided by operating activities-$-38.31M-$-27.02M-$-34.24M-$-31.42M-$-22.22M
Investments in property, plant and equipment-$-590K-$-20K-$-460K-$-1.3M-$-1.83M
Acquisitions, net$30K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-560K-$-20K-$-280K-$-1.3M-$-1.83M
Common stock issued$19.9M$101.8M$0.00$0.00$71.3M
Common stock repurchased$0.00$0.00-$-120K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$56.1M$94.3M-$-120K$20M$71.8M
Net change in cash$17.2M$67.2M-$-34.65M-$-12.74M$47.8M
Cash at end of period$120.2M$102.9M$35.7M$70.3M$83.1M
Operating cash flow-$-38.31M-$-27.02M-$-34.24M-$-31.42M-$-22.22M
Capital expenditure-$-590K-$-20K-$-460K-$-1.3M-$-1.83M
Free cash flow-$-38.9M-$-27.04M-$-34.7M-$-32.72M-$-24.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Candel Therapeutics, Inc.

        Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

        CEO
        Paul-Peter Tak
        Employees
        55
        Beta
        -0.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Candel Therapeutics, Inc. (CADL)?

        InvestorsCraft does not currently publish an intrinsic value for CADL. How the IC value is calculated.

        Is CADL undervalued?

        InvestorsCraft does not publish an undervaluation signal for CADL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.